Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02071862
Title	Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Calithera Biosciences, Inc
Indications	lung non-small cell carcinoma gastrointestinal stromal tumor triple-receptor negative breast cancer renal cell carcinoma malignant mesothelioma Advanced Solid Tumor
Therapies	Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat
Age Groups:	adult \| senior
Covered Countries	USA